Collectively, these results indicate that dual inhibition of TLR4-SPHK1 signaling synergizes with TMZ to enhance therapeutic efficacy in TMZ-resistant GBM, suppressing tumor growth and reversing M2-TAMs polarization in the tumor microenvironment. The gene discussed is TLR4; the disease is neoplasm.